Natural Capsules Limited Stock Price Today (NSE: NATCAPSUQ)
Fundamental Score
Natural Capsules Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Natural Capsules Limited share price today is ₹172.54, down 4.37% on NSE/BSE as of 16 September 2026. Natural Capsules Limited (NATCAPSUQ) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹179.63 (Cr). The 52-week high for NATCAPSUQ share price is ₹296.00 and the 52-week low is ₹136.36. The company has a Return on Equity (ROE) of -7.51% and a debt-to-equity ratio of 0.52.
Natural Capsules Limited Share Price Chart — NSE/BSE Historical Performance
Natural Capsules Limited share price chart: 14.15% return over the past month. 52-week high ₹296.00, 52-week low ₹136.36.
Natural Capsules Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹179.99 | ₹179.99 | ₹171.41 | ₹172.54 | 12.65K (Cr) | |
| ₹185.01 | ₹189.99 | ₹180.00 | ₹180.43 | 15.66K (Cr) | |
| ₹192.60 | ₹192.60 | ₹185.00 | ₹189.39 | 8.92K (Cr) | |
| ₹194.99 | ₹194.99 | ₹187.00 | ₹190.74 | 7.49K (Cr) | |
| ₹196.00 | ₹196.00 | ₹190.00 | ₹194.26 | 11.30K (Cr) | |
| ₹206.00 | ₹206.00 | ₹195.64 | ₹196.19 | 35.19K (Cr) | |
| ₹207.21 | ₹215.00 | ₹205.60 | ₹205.93 | 20.09K (Cr) | |
| ₹232.20 | ₹234.00 | ₹215.64 | ₹216.42 | 13.33K (Cr) | |
| ₹218.50 | ₹226.98 | ₹218.50 | ₹226.98 | 18.62K (Cr) | |
| ₹201.37 | ₹219.00 | ₹194.59 | ₹216.18 | 32.92K (Cr) |
Natural Capsules Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹211.36 | ₹234.00 | ₹171.41 | ₹172.54 | -18.37% | |
| ₹144.71 | ₹225.00 | ₹144.10 | ₹212.38 | +46.76% | |
| ₹149.00 | ₹154.85 | ₹137.25 | ₹143.28 | -3.84% | |
| ₹162.81 | ₹165.00 | ₹146.20 | ₹148.86 | -8.57% | |
| ₹155.01 | ₹182.80 | ₹150.00 | ₹162.62 | +4.91% | |
| ₹145.41 | ₹181.32 | ₹145.41 | ₹154.46 | +6.22% | |
| ₹144.00 | ₹165.50 | ₹136.36 | ₹144.35 | +0.24% | |
| ₹169.00 | ₹190.00 | ₹149.00 | ₹153.87 | -8.95% | |
| ₹165.99 | ₹200.49 | ₹154.99 | ₹163.96 | -1.22% | |
| ₹183.80 | ₹195.40 | ₹160.00 | ₹166.00 | -9.68% | |
| ₹206.40 | ₹215.66 | ₹173.00 | ₹185.43 | -10.16% | |
| ₹275.00 | ₹282.00 | ₹205.25 | ₹208.50 | -24.18% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Natural Capsules Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Natural Capsules Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NATCAPSUQ across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Consistent Growth Track Record (18.68% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Balanced Promoter Holding (51.26%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (-7.51%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-5.56%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-28.75%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (-1.55x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-233.75 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Natural Capsules Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Natural Capsules Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Natural Capsules LimitedNatural Capsule...Selected✓ NATCAPSUQ • 524654 | 27.7/100 | ₹172.54₹173 | ₹179.63₹179.63 | — — | -7.51%Poor -7.51% Poor | -5.56%Poor -5.56% Poor | 0.52Good 0.5 Good | — — | 18.68%Excellent 18.68% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Natural Capsules Limited PE Ratio History
Historical price-to-earnings ratio for NATCAPSUQ — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.63 | ₹166.00 | 264.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Natural Capsules Limited Dividend History
Annual cash dividends paid by NATCAPSUQ — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2024 | ₹0.93 Cr |
| FY 2023 | ₹0.77 Cr |
| FY 2022 | ₹0.62 Cr |
| FY 2021 | ₹0.37 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Natural Capsules Limited Quarterly Performance
Latest quarterly metrics for NATCAPSUQ — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
7.76%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-28.75%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
18.68%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Natural Capsules Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for NATCAPSUQ — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Natural Capsules Limited Financial Statements
Annual income statement, balance sheet and cash flow for Natural Capsules Limited (NATCAPSUQ) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Natural Capsules Limited
About NATCAPSUQ (Natural Capsules Limited)
Natural Capsules Ltd is a pioneering force in the pharmaceutical manufacturing landscape, specializing in the development and global distribution of advanced capsule solutions. Wit...h a firm commitment to quality and innovation, the company produces a diverse portfolio of hard gelatin and cellulose capsule shells, catering to the evolving needs of the pharmaceutical and nutraceutical industries. Their state-of-the-art manufacturing facilities adhere to the highest international standards, ensuring consistent product excellence and safety. The company is strategically positioned to serve both domestic and international markets, leveraging its expertise and advanced technologies to deliver superior capsule solutions to a global clientele. Focusing on specialized requirements, Natural Capsules Ltd offers a range of tailored capsule shells, each engineered to meet specific formulation and delivery demands. This includes bovine spongiform encephalopathy (BSE) and transmissible spongiform encephalopathy (TSE) free gelatin, appealing to stringent safety standards, as well as shiny gelatin and sodium lauryl sulfate-free gelatin alternatives. They also provide halal-certified gelatin, fast-release gelatin options, and customized printed gelatin/cellulose capsules for branding purposes. In addition, the company offers vegetarian and enteric capsule shells, catering to a diverse range of consumer preferences and therapeutic applications, demonstrating their dedication to delivering comprehensive solutions. Beyond capsule manufacturing, Natural Capsules Ltd has expanded its capabilities to include the formulation of pharmaceutical dosage forms specifically within capsule dosage form. This strategic integration allows them to offer comprehensive solutions, from capsule shell design to final drug product manufacturing. By combining its expertise in capsule technology with advanced formulation capabilities, the company provides its clients with end-to-end services, streamlining the drug development process and ensuring product quality. Their dedication to innovation and customer satisfaction positions them as a trusted partner for pharmaceutical companies seeking cutting-edge capsule solutions and reliable manufacturing services.
Company Details
Key Leadership
NATCAPSUQ Share Price: Frequently Asked Questions
What is the current share price of Natural Capsules Limited?
Natural Capsules Limited (NATCAPSUQ) trades at ₹172.54 on NSE and BSE. Market cap ₹179.63 (Cr). Educational data only.
What is the P/E ratio of Natural Capsules Limited?
Natural Capsules Limited has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Natural Capsules Limited?
Natural Capsules Limited has a Bull Run score of 27.7/100 based on 25+ financial parameters.
Does Natural Capsules Limited pay dividends?
Natural Capsules Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Natural Capsules Limited?
Natural Capsules Limited has ROE of -7.51%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Natural Capsules Limited?
Natural Capsules Limited has debt-to-equity of 0.52.
Is Natural Capsules Limited a good investment?
Bull Run gives Natural Capsules Limited a score of 27.7/100. This is not investment advice — consult a SEBI-registered advisor.